Home-based urinary HPV self-sampling for the detection of cervical cancer precursor lesions: attitudes and preferences from Belgian females participating in the CASUS study.
Hendrickx, Jhana O; Van Keer, Severien; Donders, Gilbertet al.
2025 • In Archives of Public Health, 83 (1), p. 32
Atitudes; CASUS; Cervical cancer screening; First-void urine; HPV; Preferences; Self-sampling; Public Health, Environmental and Occupational Health
Abstract :
[en] [en] BACKGROUND: Cervical cancer (CC) is the fourth most common cancer globally in females, caused by oncogenic infections with high-risk human papillomavirus (hrHPV) strains. Successful CC screening programs strongly depend on the participation rate of the target population. Nevertheless, it remains challenging to reach under screened populations. The CASUS study aimed to develop a complete CC screening solution based on first-void urine (FVU) self-sampling. Here we report on the usability perceptions and preferences from females that participated in the CASUS study by collecting FVU as a liquid biopsy.
METHODS: Females self-collected FVU samples at home the day before colposcopy using the Colli-Pee® UCM FV-5010, a FVU collection device prefilled with 3 mL of UCM preservative, collecting a total volume of 10mL. Afterwards, they completed a questionnaire expressing their usability perceptions and preferences regarding the device.
RESULTS: A total of 332 females (26-70y) were enrolled in the CASUS study of which 210 completed the questionnaire. Overall, 66.6% of females preferred FVU self-sampling over a physician taken cervical sample (PTS) (32.9%) for their next CC screening. Out of 159 women who reported prior experience with a urine cup, 79.2% expressed a preference for using the Colli-Pee® UCM FV-5010, while 20.8% favored the traditional urine cup. Additionally, 96.6% of females found Colli-Pee® UCM FV-5010 easy to use and 97.1% would use the device again. A total of 208 valid System Usability Score (SUS) scores were received with an average of 86.17 ± 1.03 Standard Error of Mean (SEM).
CONCLUSION: The results of this study show that the majority of females in this referral cohort would prefer to self-collect a FVU sample at-home over a PTS for their next CC screening. Moreover, Colli-Pee® UCM FV-5010 was considered an easy-to-use and well-accepted self-sampling device for CC screening in a Belgian colposcopy referral population. From a future perspective, these results highlight the possibility of home-based FVU self-sampling as a liquid biopsy in CC screening where under screened populations could be approached more easily.
TRIAL REGISTRATION: The CASUS study was registered in http://www.
CLINICALTRIALS: gov (identifier: NCT04530201).
Van Keer, Severien; Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Drie Eikenstraat 663, Edegem (Antwerp), 2650, Belgium
Donders, Gilbert; Department of Obstetrics and Gynaecology of the General Regional Hospital Heilig Hart, Kliniekstraat 45, Tienen, 3300, Belgium ; Femicare vzw, Clinical Research for Women, Gasthuismolenstraat 33, Tienen, 3300, Belgium ; Department of Obstetrics and Gynaecology, Antwerp University Hospital (UZA), Drie Eikenstraat 655, Edegem, 2650, Belgium
Weyers, Steven; Department of Obstetrics and Gynecology, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, 9000, Belgium
Doyen, Jean ; Université de Liège - ULiège > Département des sciences de la santé publique
Beyers, Koen C L; Novosanis, Bijkhoevelaan 32c, Wijnegem, 2110, Belgium
Téblick, Laura; Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Drie Eikenstraat 663, Edegem (Antwerp), 2650, Belgium
Vankerckhoven, Vanessa V J; Novosanis, Bijkhoevelaan 32c, Wijnegem, 2110, Belgium ; Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Drie Eikenstraat 663, Edegem (Antwerp), 2650, Belgium
Language :
English
Title :
Home-based urinary HPV self-sampling for the detection of cervical cancer precursor lesions: attitudes and preferences from Belgian females participating in the CASUS study.
Publication date :
2025
Journal title :
Archives of Public Health
ISSN :
0778-7367
eISSN :
2049-3258
Publisher :
BioMed Central Ltd, England
Volume :
83
Issue :
1
Pages :
32
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
EU - European Union FWO - Research Foundation Flanders
Funding text :
First. we would like to thank all females participating and completing the questionnaires in the CASUS study. We would also like to thank the study nurses and study teams at UZ Ghent. CHU de Li\u00E8ge. and the General Regional Hospital Heilig Hart Tienen for their collaboration and support in recruiting participants and documenting study data. We are grateful for the excellent scientific. administrative and logistical assistance of Nancy Kemland (Novosanis). Frank van Batenburg (Novosanis) and Annemie De Smet (VAXINFECTIO).This research was funded by H2020 Eurostars (grant number 12396). The funder did not play a role in this research. S. Van Keer is supported by a postdoctoral fellowship of the Research Foundation-Flanders (1240220 N).
L.A. Torre et al. Global Cancer in women: Burden and TrendsGlobal Cancer in women: Burden and Trends Cancer Epidemiol Biomarkers Prev 26 4 444 57 28223433
F. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 68 6 394 424
H. Sung et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 71 3 209 49
K.T. Simms et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study Lancet Oncol 20 3 394 407 30795950
M. Arbyn et al. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002–2006) PLoS ONE 9 4 e92615 24690620 3972167
A. Anttila et al. Cervical cancer screening policies and coverage in Europe Eur J Cancer 45 15 2649 58 19699081
WHO. Coverage of national cervical cancer screening program (%). The Global HealthObservatory2020; Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/coverage-of-national-cervical-cancer-screening-program-(-)
Kankeronderzoek Cv. Jaarrapport 2022 [cited2023October25th]; Available from: https://baarmoederhalskanker.bevolkingsonderzoek.be/nl
E. Gakidou S. Nordhagen Z. Obermeyer Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities PLoS Med 5 6 e132 18563963 2429949
J. Waller et al. Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study BJOG: Int J Obstet Gynecol 119 1 26 32
Staley Het al. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Reviews, 2021(9).
I. Rees et al. Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: a systematic review Prev Med 111 323 35 29203349
A.J. Chorley et al. Experiences of cervical screening and barriers to participation in the context of an organised programme: a systematic review and thematic synthesis Psycho-oncology 26 2 161 72 27072589
R.P. Bosgraaf et al. Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women Prev Med 64 108 13 24736093
A. Vorsters et al. Overcoming barriers in HPV vaccination and screening programs Papillomavirus Res 4 45 53 29179869 7268103
Y. Ge et al. HPV status in women with high-grade dysplasia on cervical biopsy and preceding negative HPV tests J Am Soc Cytopathol 8 3 149 56 31097291
S. Niu et al. Challenges in the pap diagnosis of endocervical adenocarcinoma in situ J Am Soc Cytopathol 8 3 141 8 31097290
J.D. Boone B.K. Erickson W.K. Huh New insights into cervical cancer screening J Gynecologic Oncol 23 4 282 7
M. Gök et al. Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases Br J Cancer 104 4 685 92 21266976 3049583
M. Arbyn et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Vaccine 30 F88 99 23199969
G. Ronco et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Lancet 383 9916 524 32 24192252
Pathak N et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ, 2014. 349.
M. Arbyn P.E. Castle Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program Cancer Epidemiol Biomarkers Prev 24 5 769 72 25713024
S. Van Keer et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol Gynecol Oncol 162 3 575 83 34172287
S. Van Keer et al. Analytical and clinical performance of extended HPV genotyping with BD Onclarity HPV Assay in home-collected first-void urine: a diagnostic test accuracy study J Clin Virol 155 105271 36049283
D. Ørnskov et al. Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for HPV testing among women referred for colposcopy. A cross-sectional study BMJ open 11 3 e041512 33674367 7939007
V.M. Verhoef et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial Lancet Oncol 15 3 315 22 24529697
C.S. Racey D.R. Withrow D. Gesink Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis Can J Public Health 104 2 e159 66 23618210 6973997
F. Verdoodt et al. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials Eur J Cancer 51 16 2375 85 26296294
S. Costa et al. Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening Br J Cancer 128 5 805 13 36517552
H. Nishimura et al. HPV self-sampling for cervical cancer screening: a systematic review of values and preferences BMJ Global Health 6 5 e003743 34011537 8137189
Organization WH. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights: web supplement: GRADE tables. World Health Organization; 2019.
P. Maver M. Poljak Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans Clin Microbiol Infect 26 5 579 83 31539637
Arbyn M et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ, 2008. 337.
Kyrgiou M et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ, 2014. 349.
F. Bruinsma M. Quinn The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis BJOG: Int J Obstet Gynecol 118 9 1031 41
S. Deen et al. The day we started HPV triage J Clin Pathol 69 9 822 5 27030306
A.T. Hesselink et al. Combined promoter methylation analysis of CADM1 and MAL: an Objective Triage Tool for High-Risk Human Papillomavirus DNA–Positive WomenMethylation markers to triage hrHPV-Positive women Clin Cancer Res 17 8 2459 65 21389098
F. Carozzi et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial Lancet Oncol 14 2 168 76 23261355
N. Bulkmans et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial Lancet 370 9601 1764 72 17919718
H.C. Kitchener et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial Lancet Oncol 10 7 672 82 19540162
A. Vorsters et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction Eur J Clin Microbiol Infect Dis 33 2005 14 24916950
J. Brooke SUS-A quick and dirty usability scale Usability Evaluation Ind 189 194 4 7
Brooke J, Thomas B, Weerdmeester BA, AL McClelland. 1996, Taylor and Francis, London.
J.L. Schafer Multiple imputation: a primer Stat Methods Med Res 8 1 3 15 10347857
Smaradottir B et al. Usability evaluation of a collaborative health information system. lessons from a user-centred design process. 2016.
E. Grasaas et al. iCanCope with pain: cultural adaptation and usability testing of a self-management app for adolescents with persistent pain in Norway JMIR Res Protocols 8 6 e12940
L. Téblick et al. Impact of collection volume and DNA extraction method on the detection of biomarkers and HPV DNA in first-void urine Molecules 26 7 1989 33915837 8036936
M. Arbyn et al. VALHUDES: a protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples J Clin Virol 107 52 6 30195193
H. De Pauw et al. Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study Archives Public Health 79 1 1 9
L. Cadman et al. A Randomized comparison of different vaginal self-sampling devices and urine for human papillomavirus testing—predictors 5.1. Cancer Epidemiology Biomarkers Prev 30 4 661 8
A. Leeman et al. HPV testing in first-void urine provides sensitivity for CIN 2 + detection comparable with a smear taken by a clinician or a brush‐based self‐sample: cross‐sectional data from a triage population BJOG: Int J Obstet Gynecol 124 9 1356 63
S. Van Keer et al. Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples Eur J Clin Microbiol Infect Dis 37 859 69 29417310 5916996
F.C. Ertik et al. CoCoss-Trial: concurrent comparison of Self-Sampling devices for HPV-Detection Int J Environ Res Public Health 18 19 10388 34639688 8508434
Y. Nishimura et al. Mailing human papillomavirus self-sampling kits to women under-screened for cervical cancer improved detection in cervical cancer screening in a general population study in Japan BMC Public Health 23 1 473 36906527 10008572
N.G. Campos et al. Cost-effectiveness of offering cervical cancer screening with HPV self-sampling among African-American women in the Mississippi Delta Cancer Epidemiol Biomarkers Prev 30 6 1114 21 33771846
R.T. Meenan et al. Economic evaluation of Mailed Home-based human papillomavirus self-sampling kits for Cervical Cancer Screening JAMA Netw Open 6 3 e234052 234052 36947040 10034577
S. Huntington et al. Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation BMJ open 13 6 e068940 37280031 10254906
Cocuzza C. Extended validation of human papillomavirus assays and collection devices for HPV testing on self-samples and first-void urine samples. 2021.
ISRCTN. ISRCTN13132810: urine human papillomavirus (HPV)testing for cervical pre-cancer screening.
C. Lefeuvre et al. Study protocol: randomised controlled trial assessing the efficacy of strategies involving self-sampling in cervical cancer screening Int J Public Health 67 1604284 35283720 8907121
